A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphataemia in End-Stage Renal Disease Patients on Haemodialysis (ESRD-HD)

Trial Profile

A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphataemia in End-Stage Renal Disease Patients on Haemodialysis (ESRD-HD)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Ardelyx; AstraZeneca
  • Most Recent Events

    • 01 Jun 2017 Results published in the Journal of the American Society of Nephrology.
    • 22 Jun 2016 Results published in Ardelyx media release.
    • 25 Feb 2015 Results published in Ardelyx Inc. media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top